VivoSeq
Other

Anlotinib

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Anlotinib is an early-stage landscape with 0 programs across 1 company. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

23

clinical trials

Unknown status15 · 65%
Completed7 · 30%
Recruiting1 · 4%

Clinical Trials

Trial Activity

23 trials

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
Recruiting·FFudan University·N/A·NCT06258642·39 enrolled
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
Completed·ZZhejiang University·Phase 2·NCT04080843·30 enrolled
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
Completed·—·N/A·NCT06573424·124 enrolled
A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
Completed·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT01833923·35 enrolled
A Phase II Study of Anlotinib in STS Patients
Completed·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT01878448·166 enrolled
A Phase II Study of Anlotinib in MTC Patients
Completed·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT01874873·58 enrolled
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
Completed·SShanghai Chest Hospital·Phase 1·NCT04967079·33 enrolled
A Trial of AK104 Plus Anlotinib in NSCLC
Completed·AAkeso·Phase 1/2·NCT04646330·114 enrolled
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
Unknown status·FFujian Cancer Hospital·N/A·NCT03566576·18 enrolled
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC
Unknown status·—·Phase 3·NCT04665609·80 enrolled
Study of Anlotinib in Patients With Primary Malignant Bone Tumors
Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT03527888·40 enrolled
Anlotinib or Penpulimab in Combination With RAI for DTC
Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04952493·42 enrolled
Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients
Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT05559242·30 enrolled
A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer
Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT04203719·140 enrolled
A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT05028504·86 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)